Thermo Fisher Raises Guidance; Danaher's Recovery Uneven in Mixed Results

Thermo Fisher Scientific and Danaher, two major life sciences tools companies, both reported better-than-expected second-quarter results, but their recoveries show different trajectories. Thermo Fisher posted 10% revenue growth to $11.99 billion and 13% adjusted EPS growth to $6.03. The company raised guidance citing broad-based demand improvement across pharmaceutical and biotechnology markets. Danaher's recovery remains more uneven, though it achieved high-single-digit adjusted EPS growth with improving core growth versus the previous quarter.

Thermo Fisher's Life Sciences Solutions segment grew 13% year-over-year, while Analytical Instruments returned to growth after nearly two years of weak demand. Thermo Fisher's recovery appears more broad-based across multiple segments, suggesting greater durability. The company continues investing in product innovation, including new Orbitrap mass spectrometers.

Separately, Danaher fell short of the market's revenue expectations in the first quarter of 2026 as sales rose 3.7% year on year to $5.95 billion. Its non-GAAP profit of $2.06 per share was 6.4% above analysts' consensus estimates. Adjusted EBITDA was $1.99 billion, a 33.4% margin, and management slightly raised full-year adjusted EPS guidance to $8.45 at the midpoint. Operating margin was 22.6%, in line with the same quarter last year, while organic revenue was flat year on year.

In that quarter, Danaher cited robust performance in bioprocessing and a stabilizing Life Sciences segment as key contributors, while noting that a lighter-than-usual respiratory season at Cepheid and ongoing pressure in Chinese diagnostics weighed on results. Bioprocessing demand sustained with high single-digit growth in consumables and notable equipment order growth of more than 30% year over year. The Life Sciences segment experienced early signs of recovery, especially in consumables and in China, where improved funding and commercial execution at Aldevron and Abcam contributed to positive momentum. Core revenue in Diagnostics declined due to a softer respiratory season at Cepheid and ongoing pricing pressures in China, but non-respiratory diagnostics grew mid-single digits outside China, buoyed by new menu introductions and share gains.

Danaher launched several new products, including Cytiva's Fibro dT mRNA purification platform and Beckman Coulter's strategic partnership with Automata for AI-driven automation. The launch of the Xpert GI panel at Cepheid and FDA clearance for new immunoassay tests at Beckman Diagnostics were highlighted as contributors to future growth. The pending acquisition of Masimo was described as highly strategic, expected to create both cost and revenue synergies, particularly through integration with Radiometer. Management also highlighted a strong pipeline for further M&A.

Management expects Danaher's growth to accelerate over the coming quarters, supported by bioprocessing tailwinds, new product launches, and the addition of Masimo. Some headwinds—particularly in China diagnostics and academic research—are likely to fade by year-end, though the company's guidance does not assume major market improvements. The CEO pointed to the company's position in emerging AI-driven laboratory automation and new product introductions as long-term growth drivers.